Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (original) (raw)

Data availability

The authors declare that all data supporting the findings of this study are available within the article and its Supplementary information, or available from the corresponding author upon reasonable request.

References

  1. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
    Article CAS Google Scholar
  2. Hauschild, A. et al. Dabrafenib in _BRAF_-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358–365 (2012).
    Article CAS Google Scholar
  3. Larkin, J. et al. Combined vemurafenib and cobimetinib in _BRAF_-mutated melanoma. N. Engl. J. Med. 371, 1867–1876 (2014).
    Article Google Scholar
  4. Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39 (2015).
    Article Google Scholar
  5. Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 _BRAF_-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444–451 (2015).
    Article CAS Google Scholar
  6. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
    Article CAS Google Scholar
  7. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
    Article CAS Google Scholar
  8. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
    Article CAS Google Scholar
  9. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
    Article Google Scholar
  10. Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651–1656 (2006).
    Article CAS Google Scholar
  11. Khalili, J. S. et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 melanoma. Clin. Cancer Res. 18, 5329–5340 (2012).
    Article CAS Google Scholar
  12. Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
    Article CAS Google Scholar
  13. Wilmott, J. S. et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386–1394 (2012).
    Article CAS Google Scholar
  14. Schilling, B. & Paschen, A. Immunological consequences of selective BRAF inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells. Oncoimmunology 2, e25218 (2013).
    Article Google Scholar
  15. Long, G. V. et al. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 26, 499–508 (2013).
    Article CAS Google Scholar
  16. Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).
    Article CAS Google Scholar
  17. Kono, M. et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol. Cancer Res. 4, 779–792 (2006).
    Article CAS Google Scholar
  18. Sapkota, B., Hill, C. E. & Pollack, B. P. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology 2, e22890 (2013).
    Article Google Scholar
  19. Vella, L. J. et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol. Res. 2, 351–360 (2014).
    Article CAS Google Scholar
  20. Cooper, Z. A. et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2, e26615 (2013).
    Article Google Scholar
  21. Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).
    Article CAS Google Scholar
  22. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
    Article CAS Google Scholar
  23. Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135–2147 (2005).
    Article CAS Google Scholar
  24. Wan, P. T. et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004).
    Article CAS Google Scholar
  25. Ascierto, P. et al. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248–1260 (2016).
    Article CAS Google Scholar
  26. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
    Article CAS Google Scholar
  27. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
    Article CAS Google Scholar
  28. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
    Article CAS Google Scholar
  29. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
    Article Google Scholar
  30. Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609–621 (2016).
    Article CAS Google Scholar
  31. Cooper, Z. A. et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2, 643–654 (2014).
    Article CAS Google Scholar
  32. Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241–279ra241 (2015).
    Article Google Scholar
  33. Hamid, O. et al. Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PDL1) combined with vemurafenib in _BRAF_V600 metastatic melanoma. Pigment Cell Melanoma Res. 28, 778 (2015).
    Google Scholar
  34. Sullivan, R. et al. Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (antiPDL1) combined with vemurafenib in _BRAF_V600 mutant metastatic melanoma. J. Transl. Med. 14, 9–10 (2016).
    Article Google Scholar
  35. Rapisuwon, S. et al. Analysis of the kinetics and effects of vemurafenib (V) plus cobimetinib (C) on intratumoral and host immunity in patients (pts) with _BRAF_V600 mutant melanoma (BRAFmM): implications for combination with immunotherapy. J. Clin. Oncol. 36, 9559–9559 (2018).
    Article Google Scholar
  36. Ribas, A. et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for _BRAF_-mutant advanced melanoma. Ann. Oncol. 28, v428–v448 (2017).
    Article Google Scholar
  37. Long, G. V. et al. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. Eur. J. Cancer 72, S122–S123 (2017).
    Article Google Scholar
  38. Long, G. V. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743–1754 (2016).
    Article CAS Google Scholar
  39. Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102–4109 (2016).
    Article CAS Google Scholar
  40. Wongchenko, M. J. et al. Gene expression profiling in _BRAF_-mutated melanoma reveals patient subgroups with poor outcomes to vemurafenib that may be overcome by cobimetinib plus vemurafenib. Clin. Cancer Res. 23, 5238–5245 (2017).
    Article CAS Google Scholar

Download references

Acknowledgements

Research support was provided by S. Lecagoonporn (MD Anderson Cancer Center, Houston, TX, USA). Medical writing support was provided by M. Sweetlove and J. Sah (ApotheCom, San Francisco, CA, USA) and was funded by F. Hoffmann-La Roche Ltd.

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Ryan J. Sullivan
  2. The Angeles Clinic and Research Institute, Los Angeles, CA, USA
    Omid Hamid
  3. University of Colorado Cancer Center, Aurora, CO, USA
    Rene Gonzalez & Karl D. Lewis
  4. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
    Jeffrey R. Infante
  5. Sarah Cannon Research Institute/Florida Cancer Specialists & Research Institute, Sarasota, FL, USA
    Manish R. Patel
  6. Dana-Farber Cancer Institute, Boston, MA, USA
    F. Stephen Hodi
  7. MD Anderson Cancer Center, Houston, TX, USA
    Hussein A. Tawbi & Patrick Hwu
  8. Genentech, Inc., South San Francisco, CA, USA
    Genevive Hernandez, Matthew J. Wongchenko, YiMeng Chang, Louise Roberts, Marcus Ballinger, Yibing Yan & Edward Cha

Authors

  1. Ryan J. Sullivan
    You can also search for this author inPubMed Google Scholar
  2. Omid Hamid
    You can also search for this author inPubMed Google Scholar
  3. Rene Gonzalez
    You can also search for this author inPubMed Google Scholar
  4. Jeffrey R. Infante
    You can also search for this author inPubMed Google Scholar
  5. Manish R. Patel
    You can also search for this author inPubMed Google Scholar
  6. F. Stephen Hodi
    You can also search for this author inPubMed Google Scholar
  7. Karl D. Lewis
    You can also search for this author inPubMed Google Scholar
  8. Hussein A. Tawbi
    You can also search for this author inPubMed Google Scholar
  9. Genevive Hernandez
    You can also search for this author inPubMed Google Scholar
  10. Matthew J. Wongchenko
    You can also search for this author inPubMed Google Scholar
  11. YiMeng Chang
    You can also search for this author inPubMed Google Scholar
  12. Louise Roberts
    You can also search for this author inPubMed Google Scholar
  13. Marcus Ballinger
    You can also search for this author inPubMed Google Scholar
  14. Yibing Yan
    You can also search for this author inPubMed Google Scholar
  15. Edward Cha
    You can also search for this author inPubMed Google Scholar
  16. Patrick Hwu
    You can also search for this author inPubMed Google Scholar

Contributions

R.J.S., O.H., M.B., E.C. and P.H. designed the study. R.S., O.H., P.H., R.G., J.R.I., M.R.P., F.S.H., K.D.L., H.A.T., G.H., Y.Y. and M.J.W. provided study material, patients and expert guidance. R.J.S., O.H., M.J.W., Y.Y., Y.C., L.R., M.B., E.C. and P.H. contributed to data analysis and interpretation. All authors reviewed, revised and provided input on the manuscript.

Corresponding author

Correspondence toRyan J. Sullivan.

Ethics declarations

Competing interests

This study was funded by F. Hoffman-La Roche Ltd. R.J.S. reports personal fees from Amgen, Merck, Genentech, Array and Novartis; research grants from Amgen and Merck; and clinical trial support from Merck, Genentech and Novartis during the conduct of the study; and by personal fees from Compugen, Replimune and Syndax outside the submitted work. O.H. reports advisory board fees from Roche and speaker bureau fees from Genentech during the conduct of the study; advisory board fees from Amgen, Novartis and Bristol-Myers Squibb; speaker bureau fees from Amgen, Bristol-Myers Squibb, Novartis and Array Biopharma; and research support paid to institution from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Merck Serono, MedImmune, Novartis, Pfizer, Rinat and Roche outside the submitted work. R.G. reports personal fees and grants from Roche/Genentech during the conduct of the study, personal fees and grants from Bristol-Myers Squibb and Novartis; and grants from Merck and Array Biopharma outside the submitted work. J.R.I. reports consultancy fees from BioMed Valley and Armo Biosciences and employment with Janssen Pharmaceuticals outside the submitted work. M.R.P. reports no competing interests. F.S.H. reports clinical trial support paid to institution from Genentech during the conduct of the study; consultancy fees from Genentech, Merck, Novartis, Bristol-Myers Squibb, Aduro, Partner Therapeutics, EMD Serono, Sanofi and Celldex; advisory board fees from Apricity; and research grants paid to institution from Bristol-Myers Squibb outside the submitted work; F.S.H. also reports an issued patent for Therapeutic Peptides and pending patents for MICA Related Disorders and Angiopoietin-2 as Therapeutic Target for Cancer. K.D.L. reports grants from Roche/Genentech during the conduct of the study and consultancy fees from Roche/Genentech outside the submitted work. H.A.T. reports grants and personal fees from Roche/Genentech during the conduct of the study; and grants and personal fees from Bristol-Myers Squibb, Merck and Novartis outside the submitted work. G.H. reports employment with Roche. M.J.W. reports employment and stock ownership with Genentech/Roche and stock ownership with ARIAD Pharmaceuticals. Y.C. reports employment with Genentech/Roche. L.R. reports employment with Genentech/Roche. M.B. reports employment and stock ownership with Genentech/Roche. Y.Y. reports employment with Genentech/Roche and stock ownership with Genentech/Roche. E.C. reports employment and stock ownership with Genentech/Roche. P.H. reports consultancy and advisory fees from Dragonfly, GlaxoSmithKline, Immatics and Sanofi outside the submitted work.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Study design and patients.

a, Patients received at least one dose of atezolizumab during the combination treatment period (safety population). b, Patients with progression after prior checkpoint inhibitor therapy (mandatory serial biopsy). c, Checkpoint inhibitor-naive patients (mandatory serial biopsy). d, checkpoint inhibitor-naive patients (no mandatory serial biopsy).

Extended Data Fig. 2 Longitudinal change in tumor burden.

a,b, Longitudinal change in tumor burden in: patients treated with atezolizumab + vemurafenib (n = 17) (a) and patients treated with atezolizumab + cobimetinib + vemurafenib (n = 39) (b). PD, progressive disease.

Extended Data Fig. 3 CD8+ T cells in the tumor center.

Representative images of CD8+ T cells in the tumor center before and after cobimetinib + vemurafenib treatment in 3 of 6 patients treated in the dose-escalation study phase. Numbers in each panel of a represent percentage of CD8+ cells in the tumor center. CR, complete response; SD, stable disease.

Extended Data Fig. 4 Survival by PD-L1 expression.

a–d, Kaplan–Meier curves of: PFS according to PD-L1 expression in patients treated with atezolizumab + vemurafenib (a); OS according to PD-L1 expression in patients treated with atezolizumab + vemurafenib (b); PFS according to PD-L1 expression in patients treated with atezolizumab + cobimetinib + vemurafenib (c); and OS according to PD-L1 expression in patients treated with atezolizumab + cobimetinib + vemurafenib (d).

Extended Data Fig. 5 PFS by pre-treatment CD8+ T cell infiltration status.

a,b, PFS according to pre-treatment CD8+ T cell infiltration by CD8+ immunohistochemistry with: atezolizumab + vemurafenib (a) and atezolizumab + cobimetinib + vemurafenib (b). c,d, PFS according to pre-treatment CD8+ T cell infiltration by Teff signature with: atezolizumab + vemurafenib (c) and atezolizumab + cobimetinib + vemurafenib (d).

Extended Data Fig. 6 Gating strategies for FACS.

a,b, Gating strategies for FASC panels for: T cell activation/proliferation (a) and regulatory T cells (b).

Supplementary information

Rights and permissions

About this article

Cite this article

Sullivan, R.J., Hamid, O., Gonzalez, R. et al. Atezolizumab plus cobimetinib and vemurafenib in _BRAF_-mutated melanoma patients.Nat Med 25, 929–935 (2019). https://doi.org/10.1038/s41591-019-0474-7

Download citation